natgillin/translations-raw huggingface dataset:
The compound for use according to claim 23 wherein the viral infection is caused by a virus selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus. 
Primjena prema patentnom zahtjevu 6, gdje je virusna infekcija uzrokovana virusom koji je odabran iz grupe koja se sastoji od denga virusa, virusa žute groznice, virusa Zapadnog Nila, virusa Japanskog encefalitisa, virusa krpeljnog meningoencefalitisa, Kunjin virusa, virusa encefalitisa Doline Murray, virusa encefalitisa St. Louis, virusa Omsk hemoragične groznice, virusa goveđe virusne dijareje, Zika virusa 1 virusa hepatitisa C. HR P20180572 T1
and their salts and tautomers, desmotrops or optical isomers and the salts thereof 
i njihove soli i tautomeri, dezmotropi ili optički izomeri, kao i njihove soli.
Tumour volume was assessed twice weekly by bilateral Vernier calliper measurement, using the formula (length×width)×√(length×width)×(π/6), where length was the longest diameter across the tumour, and width was the corresponding perpendicular. 
Volumen tumora računat je dva puta tjedno pomoću pomične mjerke Vernier i formule (duljina x širina) x v (duljna x širina) x (1/6), pri čemu je za duljinu uzet najveći promjer tumora, a širina je bila odgovarajuća duljina okomice.
Finally, the TCF was incubated under agitation at a temperature of 37° C. At day 4, the culture was transferred to a TCF175 cm2and diluted to 120 mL by adding fresh and preheated medium SM-005. 
Naposljetku, boca za kulturu stanica je inkubirana uz trešnju pri temperaturi od 37 *C. 4. dana stanična je kultura prebačena u TCF 175 cm? i razrijeđena na 120 mL dodatkom svježeg prethodno zagrijanog SM-005 medija.
providing said first metal plate, acoustic insulation layer and second metal plate, 
osiguravanju navedene prve metalne ploče, sloja zvučne izolacije i druge metalne ploče, -
An agent for testing mental conditions selected from the group consisting of mental fatigue, physical fatigue, stress, blue mood, comfortable mood, uncomfortable mood, dysthymia, compulsive, panic, anxiety, phobia, anthropophobia, social phobia, tension, working intensity, learning intensity, depression, schizophrenia, mental conditions similar to depression, mental conditions similar to schizophrenia and suicide risk, which comprises at least two kinds of molecules selected from the group consisting of molecules specifically recognizing IL-1B, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-Y, IFN-a, IP-10, MCP-1, MIP-1a, MIP-1B, PDGF-BB, RANTES, TNF-a, VEGF, CSF-2, TGF-B, neurotrophin 5, MCP-3, B-2-microglobulin, angiotensin II, CSF-3, CXC chemokine ligand 1, CXC chemokine ligand 5 and HGF, respectively. 
Uporaba in vitro ispitnog sredstva za testiranje mentalnih stanja, naznačena time, da su ta stanja odabrana iz skupine koju čine: mentalna iscrpljenost, fizička iscrpljenost, stres, anksioznost, depresija i shizofrenija, pri čemu ispitno sredstvo sadrži najmanje osam vrsta protutijela odabranih iz skupine protutijela koja specifično prepoznaju svakog dotičnog prema sljedećem popisu: IL-1B, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, eotaksin, osnovni FGF, G-CSF, GM-CSF, IFN-Y, IFN-a, IP-10, MCP-1, MIP-1a, MIP-1B, PDGF-BB, RANTES, TNF-a, VEGF, CSF-2, TGF-B, neurotrofin 5, MCP-3, B-2-mikroglobulin, angiotenzin II, CSF-3, CXC ligand kemokina l, CXC ligand kemokina 5 i HGF.
A compound of claim 7, of formula (I-L): 
Spoj sukladno patentnom zahtjevu 5, formule (I-L): ž a
Size of experimental groups: 10 
Veličina skupine pokusa: 10
1-(B-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene), or pharmaceutically acceptable salt thereof present in an amount within the range of from 40% to 60% by weight; 
(a) 1(B-D-glukopiranozil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil] benzen), ili njegovu farmaceutski prihvatljivu sol u količini u rasponu od 40% do 60%, po masi;
The method of claim 1, wherein the polymer dispersion dust control agent is applied in an amount of 0.2 to 3 L per m2 of the surface to be treated. 
Korištenje sukladno zahtjevu 1, naznačeno time da se sredstvo za kontrolu prašine stavlja u količini od 0,2 do 3 L po m2 površine koje je potrebno tretirati.
are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-1 or ring R-2 
R* i R* su uzeti zajedno sa kontinuiranim vezujućim atomima dušika i ugljika tako da formiraju izborno supstituiran prsten R-1
Still another embodiment comprises compositions comprising 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof, a crystallization inhibitor and a pH modifier, said composition providing a measurable improvement in dissolution rate of the ionizable drug. 
Smjesa koja sadrži 1-(6-amino-3,5-difluoropiridin-2-il)-8-klor-6-fluor-7-(3-hidroksiazetidin-1- 1l)-4-okso-1,4-dihidrokinolin-3-karboksilnu kiselinu ili njezinu sol, inhibitor kristalizacije izabran iz skupine koja obuhvaća hidroksipropilmetilcelulozu, polivinilpirolidon i hidroksipropilcelulozu te modifikator pH, naznačena time, da smjesa ima mjerljivo poboljšan stupanj otapanja 1-(6- amino-3,5-difluoropiridin-2-il)-8-klor-6-fluor-7-(3-hidroksiazetidin-1-i1)-4-okso-1,4- dihidrokinolin-3-karboksilne kiseline ili njezine soli.
The polynucleotide according to claim 4, comprising the nucleotide sequences of SEQ ID NO: 61 and 65. 
Polinukleotid u skladu s patentnim zahtjevom 4, naznačen time što sadrži nukleotidne sljedove SEQ ID NO: 61 i 65.
The method of claim 10, wherein said clostridial neurotoxin is of serotype A or E, or is a biologically active derivative thereof. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time, da je rečeni klostridijski neurotoksin od sereotipa A ili E ili je biološki aktivan derivat istih.
Amisulpride for use in the therapy of a condition which is chemotherapy-induced or radiation-induced nausea and vomiting. 
Amisulprid za uporabu u liječenju post-operativne mučnine i povraćanja.
Figure 2 is a diagram of the interior of the receiver used in a present invention, and indicates its various connections and components; 
Slika2 je dijagram unutrašnjosti prijemnika koji se koristi u opisanom izumu, te prikazuje različite spojeve i komponente.
reacting Compound 8 with Na2S2O5 to produce Compound 9: 
(b) reakciji Spoja 8 s Na,S205 kako bi se dobilo Spoj 9:
aromatic R2 H, alkyl such as an isobutyl group, olefinic, aromatic group such as Ph, O- 
H, alkil kao što je izobutil skupina, olefin skupina, aromatska skupina kao što je Ph, O-alkil, Oolefinska ili O-aromatska
The pharmaceutical composition of claim 5, wherein the Mtb72f fusion protein is a polypeptide consisting of residues 1 and 8-729 of SEQ ID NO:2 optionally with a His tag inserted following the initial Met residue. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što je fuzijski protein Mtb72f polpeptid koji se sastoji od ostataka 1 i 8-729 iz SEQ ID NO:2, izborno s ubačenim biljegom His iza početnog ostatka Met.
cocoa butter in an amount of from about 60% to about 80% by weight of the total composition 
kakao maslac u količini od 60% do 80 masenih% ukupnog pripravka
Use according to anyone of claims 1 and 4, or HfO2 nanoparticles or HfO2 nanoparticles' aggregates for use according to anyone of claims 2, 3 and 4, wherein said ionizing radiations are selected in the group consisting of X-Rays, Y-Rays, electron beams and radioisotope emissions. 
Uporaba prema bilo kojem od zahtjeva 1 1 4, ili nanočestice HfO, ili agregati nanočestica HfO, za uporabu prema bilo kojem od zahtjeva 2, 3 i 4, gdje su spomenuta ionizirajuća zračenja odabrana iz skupine koju čine X-zrake, y-zrake, elektronski snopovi i zračenja radioizotopa.
In certain embodiments, the present invention is directed to a transdermal delivery device comprising a backing layer; and a drug-containing layer in contact with one surface of the backing layer, the drug-containing layer comprising an effective amount of an opioid agonist and a plurality of microspheres dispersed in the drug-containing layer, the microspheres consisting essentially of an opioid antagonist and a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (e-caprolactones), polyanhydrides, albumin, blends and copolymers thereof. 
Uređaj za transdermalnu dostavu prema patentnom zahtjevu 4, naznačen time da se mikrosfere sastoje u osnovi od opioid antagonista i polimera izabranog iz skupine koje se sastoji od poliestera, polietera, poli(ortoestera), polisaharida, ciklodekstrina, kitosana, poli (I-kaprolaktona), polianhidrida, albumina, njihovih smjesa i kopolimera.
each R5 and R6 is independently selected from alkoxy, alkyl, aryl, halo, haloalkyl, hydroxy, and -NRaRb, wherein the alkyl can optionally form a fused three-to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups; 
svaki R5 i R6 je nezavisno izabran između alkoksi, alkil, aril, halo, haloalkil, hidroksi, i -NRaRb, gdje alkil može po izboru formirati fuzionirani tri- do šesteročlani prsten sa susjednim atomom ugljika, gdje je tri- do šesteročlani prsten po izboru supstituiran s jednom ili dvije alkilne skupine;
An adjusting tool system for adjusting the accuracy of a voltage divider by using a secondary unit to be connected to the voltage divider, the adjusting tool system comprising: 
Prilagodni alatni sustav (3) za podešavanje preciznosti naponskog djelitelja pomoću sekundarne jedinice (2) koja se treba spojiti s naponskim djeliteljem, naznačen time, da obuhvaća sljedeće:
The prebiotic, non digestible oligo- and polysaccharides fulfil dual roles in the sugar replacement composition: they are versatile ingredients, which function as functional and bulk sugar replacements, and as source of prebiotic fibres. 
Prebiotički, neprobavljivi oligosaharidi 1 polisaharidi imaju dvojnu ulogu u sastavinama koje zamjenjuju šećer: oni su svestrani sastojci koji djeluju kao nadomjesci koji šećer mogu zamijeniti i funkcijski i kao sredstvo koja povećava masu, a istodobno su i izvor prebiotičkih vlakana.
The soft chewable veterinary composition of paragraph 4, wherein the one or more fillers is soy protein fines, corn starch, or a mixture thereof 
Gi Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 1, naznačen time, da farmaceutski prihvatljiv nosač obuhvaća jedno ili više punila.
an LDPC decoder configured to LDPC-decode the bit-deinterleaved PLP data; and 
LDPC dekoder konfiguriran za LDPC-dekodiranje PLP podataka rspletenih bitova; i
an amino terminal segment comprising a first TGFB binding domain of TGFB receptor type II, 
amino terminalni segment, koji sadrži prvu TGFB-vežuću domenu receptora TGFB tip II,
biocompatible poly(lactide-co-glycolide) (PLGA) copolymer comprising lactic acid and glycolic acid monomers, wherein the monomers are present at a monomer ratio of lactic to glycolic acid of 48:52 to 52:48, the copolymer has an inherent viscosity in the range of 0.25-0.48 dl/g as measured in chloroform at 25° C. and at a concentration of 0.1% wt/v with an Ubbelohde size 0c glass capillary viscometer; wherein 
barem otapalo mješljivo s vodom s dipolnim momentom u rasponu od 3,9-43 D, naznačeno time što je spomenuto otapalo DMSO biokompatibilni polimer ima intrinzičnu inherentnu viskoznost u rasponu od 0,16-0,60 dl/g mjerenu u kloroformu pri 25°C i pri koncentraciji od 0,1%; a koncentracija biokompatibilnog polimera sadržana je u rasponu od 25%-50%, a postotak težine polimera na temelju ukupne otopine polimera;
The use of the thermoplastic film of any of claims 1 to 15, or the product of any of claims 16 to 18, for packaging. 
Uporaba termoplastične folije 1z bilo kojeg od zahtjeva 1 do 101ili 12, ili proizvod iz zahtjeva 11, za pakiranje, za primjenu silaže 1li za ručno pakiranje.
The composition of claim 5, wherein the compound is a composition of formula wherein q, r, and s are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. 
Spoj u skladu s patentnim zahtjevom 2, pri čemu je formula spoja pri čemu q, r i s su svaki neovisno 1, 2, 3, 4, 5, 6, 7, 8, 9 ili 10.
Secondly, sexual dysfunction is a side effect common to all SSRIs. 
Drugo, zajednička nuspojsva svim SSRI je seksualna disfunkcija.
Preferably, compounds of the present invention possess activity as antagonists or inverse agonists of the CB-1 receptor, and may be used in the treatment of diseases or disorders associated with the activity of the CB-1 receptor. 
Poželjno, spojevi prikazanog izuma posjeduju aktivnost kao antagonisti ili inverzni agonisti CB-1 receptora i mogu se upotrijebiti u liječenju bolesti ili poremećaja koje su povezane sa aktivnošću CB-I1 receptora.
The composition for use according to claim 11, wherein the compounds are linked with a cleavable or non-cleavable linker. 
Smjesa za uporabu prema zahtjevu 8, gdje su spojevi povezani linkerom koji se može ili ne može razgraditi.
A method according to claim 15, wherein the manufacturing volume information is obtained from ID codes transmitted to the checking center (30). 
Metoda u skladu s patentnim zahtjevom 15, naznačena time, da se informacija o proizvodnom volumenu dobivena iz ID kodova predaje u kontrolni centar (30).
The method of claim 1, wherein the quantity of said fluid synthetic substance introduced in the cavity during said saturation step and an expansion degree thereof by chemical reaction are adapted to produce, as an effect of the expansion of said quantity of fluid synthetic substance, a state of permanent tension on walls that delimit the cavity. 
Postupak prema zahtjevu 1, naznačen time, da su količina spomenute tekuće sintetičke tvari (4) unešene u šupljinu (1) prilikom spomenutog koraka saturiranja i njen stupanj proširenja kemijskom reakcijom, podešeni da proizvedu stanje stalnog pritiska na stijenke (2) koje omeđuju šupljinu (1), kao učinak proširenja spomenute tekuće sintetičke tvari.
The compound of claim 1 selected from the group consisting of: 
Tvar iz patentnog zahtjeva 1 odabrana iz grupe koja se sastoji od:
The torpedo of Claim 6, wherein the external heat source includes adding exhaust gasses from a motor (98). 
Torpedo prema zahtjevu 6, naznačen time da vanjski izvor topline uključuje dodavanje ispušnih plinova iz motora
Preferably, the request provided by the client to the server comprises the context information about the context of the client. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što upit koji klijent šalje serveru sadrži kontekstne informacije o kontekstu klijenta.
A compound for use according to claim 18 wherein the treatment of diseases and disorders is treatment of neutrophilic dermatoses selected from Pyoderma gangrenosum, Sweet's syndrome, severe acne and neutrophilic urticaria. 
Spoj za uporabu prema zatjevu 18, naznačen time, da liječenje bolesti 1 poremećaja je liječenje neutrofilnih dermatoza koje su odabrane od Pyoderma gangrenosum, slatkog sindroma, teških akni i neutrofilne urtikarije.
A method of treating, managing or preventing a disease or disorder comprising administering to a patient a solid form of any of items 1-62, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, hemoglobinopathy or a related disorder, or a TNFa related disorder. 
Čvrsti oblik u skladu s bilo kojim od patentnih zahtjeva 1 do 9 ili farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 10 do 13, naznačeni time što su namijenjeni upotrebi u postupku liječenja, zbrinjavanja ili sprječavanja bolesti ili poremećaja, gdje je bolest ili poremećaj rak, poremećaj povezan s angiogenezom, bol, degeneracija makule ili slični sindrom, kožna bolest, plućni poremećaj, poremećaj povezan s azbestom, parazitarna bolest, imunodeficijancijski poremećaj, poremećaj CNS-a, ozljeda CNS-a, ateroskleroza ili slični poremećaj, disfunkcionalan san ili slični poremećaj, hemoglobinopatija ili slični poremećaj ili poremećaj povezan s TNFa.
A compound as defined in any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use in the treatment of allergic rhinitis. 
Spoj u skladu s patentnim zahtjevom 2 ili patentnim zahtjevom 3, naznačen time što je namijenjen upotrebi u liječenju alergijskog rinitisa.
The “layer” is a synonym of a stream. 
i Now4lsymb "nital je produkt Mcwsisc
The reaction mixture was stirred for 2 h at room temperature and then 44.05g (292.07 mmol) of 4-oxo-piperidine-1-carboxylic acid ethyl ester in 230 ml of anhydrous tetrahydrofuran was added dropwise over 30 min. 
Reakcijsku smjesu miješa se 2 sata na sobnoj temperaturi, a zatim se 30 minuta ukapava 44,05 g (292,07 mmol) etilnog estera HR P20070328 T3 4-oksopiperidin-1-karboksilne kiseline u 230 ml bezvodnog tetrahidrofurana.
Ultrafiltration is useful for removal of small molecular weight components in the eluates resulting from previous chromatrographic steps. 
Ultrafiltracija je korisna za odstranjivanje komponenata s malim molekularnim masama iz eluata koji su dobiveni ranijim kromatografskim koracima.
A cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain, wherein said first domain is deimmunized and comprises a CDR-H1 region comprising an amino acid sequence as depicted in SEQ ID NO: 88, a CDR-H2 region comprising an amino acid sequence as depicted in SEQ ID NO: 90 or 92 and a CDR-H3 region comprising an amino acid sequence as depicted in SEQ ID NO: 96; and wherein said first domain comprises a CDR-L1 as depicted in SEQ ID NO: 98 or 100, a CDR-L2 as depicted in SEQ ID NO: 102 and a CDR-L3 as depicted in SEQ ID NO: 104; and wherein said first domain further comprises in its framework H1 the sequence VKK and wherein the transition sequence between framework H1 and CDRH1 region comprises the sequence Ala-Ser-Gly-Tyr-Thr-Phe (ASGYTF; SEQ ID NO: 233). 
Citotoksički aktivan specifičan vezujući konstrukt za CD3 koji sadrži prvu domenu koja se specifično veže za ljudski CD3 i drugu vezujuću domenu na bazi Ig-a, pri čemu je prva domena deimunizirana i sadrži CDR-H1 regiju sa sekvencom aminokiselina kako je prikazano u SEQ ID NO: 88, CDR-H2 regiju sa sekvencom aminokiselina kako je prikazano u SEQ ID NO: 90 ili 92 i CDR-H3 regiju sa sekvencom aminokiselina kako je prikazano u SEQ ID NO.: 96, 108,119, 120, 121, 122, 123, 124, 125, 126 ili 127; i pri čemu prva domena dalje sadrži u svom okviru H1 sekvencu VKK i gdje prijelazna sekvenca između okvira H1 i CDRH1 regije obuhvaća sekvencu Ala-Ser-Gly-Tyr-Thr-Phe (ASGYTF; SEQ ID NO.: 233).
treating a compound of formula (II): 
(a) obradu spoja formule (III):
A counter as claimed in claim 8 wherein said first engagement means is deflected radially outwardly after a predetermined degree of rotation of said first ring member, said predetermined amount of rotation of said first ring member being less than a full rotation of said first ring member about said common axis. 
Brojač kao što je navedeno u zahtjevu 5 naznačeno time da se navedeno prvo sredstvo uključenja (704) radijalno deflektira prema van nakon predodređenog stupnja rotacije navedenog prvog prstenastog elementa (201), navedeni predodređeni stupanj rotacije navedenog prvog prstenastog elementa bivajući manji od pune rotacije navedenog prvog prstenastog elementa oko navedene zajedničke osi.
Furthermore, Axford L. et al. 
Nadalje Axford et al.
A method according to Claim 5 wherein the polyolefinic material of the outer sealing layer B also comprises at least one polyolefinic component derived from a monomeric olefin having a carbon chain length y. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što poliolefinski materijal vanjskog brtvenog sloja B također sadrži najmanje jednu poliolefinsku komponentu koju se dobiva iz monomernog olefina čija je duljina ugljičnog lanca y.
The detection device of claim 18, wherein the first mobilizable detector comprises an Fc-binding molecule conjugated to a first detectable entity, and wherein the Fc-binding molecule is protein A and/or protein G. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što prvi detektor sadrži molekulu koja se veže na Fc, konjugiranu s prvim detektibilnim entitetom, te što je molekula koja se veže na Fc protein A i/ili protein G.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least three chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, and CCL5/RANTES and which does not bind to CCL2/MCP-1 comprising a heavy and light chain CDR sequence combination (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) of SEQ ID NO: 43/44/45/48/49/50, or which competes for binding to CCL3/MIP-1a, CCL4/MIP-1B, and CCL5/RANTES, with an antibody or antigen binding fragment comprising a heavy and light chain CDR sequence combination of SEQ ID NO: 43/44/45/48/49/50. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje tri kemokinima odabrana iz skupine koju čine CCL3/MIP-1a, CCL4/MIP-1f, i CCLS/RANTES, a koji se ne veže na CCL2/MCP-I i koji sadrže kombinacije CDR nizova teških i lakih lanaca (HCDR1/HCDR2/HCDR3/LCDRI1/LCDR2/LCDR3) SEQ ID NO: 43/44/45/48/49/50, ili koji se natječe za vezivanje to CCL3/MIP-1a, CCL4/MIP-1B, i CCLS/RANTES, s antitijelom ili fragmentom koji veže antigen i sadrži kombinacije CDR nizova teških i lakih lanaca SEQ ID NO: 43/44/45/48/49/50.
A process of claim 7, wherein the compound of formula V is isolated as and/or purified via formation of a bisulfite adduct of formula VI wherein Z represents an alkali metal. 
spoj formule V se izolira kao i/ili pročišćava putem formiranja bisulfitnog adukta formule VI pri čemu Z predstavlja alkalni metal.
Utilizing either alcohol (AG′) or alcohol (AG″) a variety of ethers can be prepared. 
Korištenjem bilo alkohola (AG') ili alkohola (AG") mogu se pripremiti različiti eteri.
Formulations suitable for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate. 
Formulacije prikladne za vaginalnu primjenu mogu biti predstavljene kao pesari, tamponi, kreme, gelovi, paste, pjene ili sprejevi koji kao dodatak aktivnom sastojku sadrže takve podloge koje su poznate u struci kao odgovarjuće.
contacting the first enriched plasma-derived target protein composition with a chromatographic resin under conditions suitable to bind at least one impurity; and 
(i) stavljanje u doticaj prvog obogaćenog sastava ciljanog proteina izvedenog iz plazme s kromatografskom smolom, pod uvjetima koji su pogodni za vezanje najmanje jedne nečistoće; 1
An antibody produced from a hybridoma cell line deposited at CBA-ICLC of Genoa (Italy) as PD 12002 or a derivative of said hybridoma cell line. 
osiguravanje hibridomske stanične linije deponirane u CBA-ICLC u Genovi (Italija) kao PD 12002;
In addition to active materials the core may contain additives conventional to the art of compressed tablets. 
Osim aktivnih tvari, jezgra može sadržavati dodatke koji su uobičajeni u struci za komprimirane tablete.
The tower section according to claim 1, wherein the tower section has a tubular shape with a polygonal cross-section, each side of the polygon defining a facet of the tower section. 
Segment (1) stupa prema zahtjevu 1, naznačen time što ima cjevasti oblik s višekutnim poprečnim presjekom, pri čemu svaka stranica ovog mnogokuta određuje jednu od strana segmenta (1) stupa.
A cylinder lock of the kind comprising 
Cilindar brava u izvedbi koja sadrži